Depressive Disorders

116 questions

Question 1Question →

Match each clinical presentation of a patient with a depressive disorder to the most appropriate next step in clinical management.

Click a left item, then click its matching right item

Items

An 81-year-old male with severe depression who has refused all food and fluids for a week, resulting in hospitalization for acute renal failure and dehydration.
A 39-year-old female whose depressive symptoms remitted on fluoxetine, but who now requests a medication change due to persistent, distressing anorgasmia.
A 22-year-old university student prescribed citalopram for low mood three weeks ago, now brought to the emergency department for severe agitation, hyper-religiosity, and going without sleep for four days.
A 48-year-old female who reports a 40 percent reduction in depressive symptoms after eight weeks of maximum-dose escitalopram, but continues to struggle with severe residual anhedonia.

Matches

Show answer & explanation

Answer

The 81-year-old refusing food requires urgent electroconvulsive therapy. The 39-year-old with sexual dysfunction should cross-taper to bupropion. The 22-year-old with manic symptoms must have the antidepressant discontinued immediately. The 48-year-old with a partial response should be augmented with an atypical antipsychotic.
Each patient represents a critical decision point in the management of depressive disorders. Life-threatening physiological decline requires ECT, SSRI-induced sexual dysfunction is managed with bupropion, treatment-emergent mania requires stopping the antidepressant, and partial SSRI responders benefit from augmentation.

Step-by-Step Solution

1
Assess the severity and safety profile of the 81-year-old male.
The patient is at imminent risk of death from dehydration and acute renal failure.
Life-threatening emergencies in major depressive disorder (like severe suicidality or starvation) require the fastest acting treatment, which is electroconvulsive therapy (ECT).
2
Identify the primary medication adverse effect in the 39-year-old female.
The patient is experiencing SSRI-induced sexual dysfunction (anorgasmia).
Switching to a non-serotonergic agent like bupropion is standard management for resolving sexual side effects while maintaining antidepressant efficacy.
3
Evaluate the new acute symptoms in the 22-year-old university student.
The patient exhibits classic signs of treatment-emergent mania (agitation, hyper-religiosity, decreased need for sleep).
Antidepressants can unmask bipolar disorder. All offending antidepressants must be stopped immediately to halt the manic episode before adding mood stabilizers.
4
Analyze the treatment response in the 48-year-old female.
The patient has had a partial response to an optimized, maximum dose of an SSRI.
Augmentation strategies (e.g., with an atypical antipsychotic, lithium, or thyroid hormone) are preferred over switching when there is a significant but incomplete response to the current medication.

Key Concept

Pharmacological and Somatic Management of Depressive Disorders and Complications
Question 2Question →

A 32-year-old man presents to the outpatient clinic with a 2-month history of persistent sadness, profound fatigue, early morning awakening, and difficulty concentrating at work. He reports that his symptoms have led to a recent poor performance review. He denies suicidal ideation, psychotic symptoms, or active medical problems. Physical examination and baseline laboratory studies are unremarkable. You suspect major depressive disorder (MDD) and plan to initiate treatment. Arrange the following clinical management steps in the most appropriate chronological sequence, assuming the patient eventually requires treatment escalation due to an initial inadequate response.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first screen for bipolar disorder, then initiate an SSRI, follow up in 4-6 weeks to assess efficacy, and finally augment or switch if the initial trial is unsuccessful.
The standard sequence for managing a new presentation of major depressive disorder begins with diagnostic safety—specifically, screening for a history of mania or hypomania to rule out bipolar disorder and avoid antidepressant-induced manic switching. Once unipolar depression is confirmed, a first-line agent (such as an SSRI) is initiated. Because these medications take time to alter receptor sensitivity and promote neurogenesis, a 4 to 6 week trial is necessary to accurately assess clinical efficacy. Only after this trial period is completed and deemed inadequate should the physician escalate therapy by augmenting the current medication or switching to an alternative agent.

Step-by-Step Solution

1
Identify the primary prerequisite diagnostic safety check before starting antidepressants.
Screening for manic/hypomanic episodes is identified as the first mandatory step.
Antidepressants can trigger mania in patients with undiagnosed bipolar disorder.
2
Determine the initial pharmacological treatment intervention.
Initiating an SSRI monotherapy follows the screening.
SSRIs are standard first-line treatments for unipolar major depressive disorder.
3
Establish the correct timeframe for evaluating the initial treatment.
Reassessing in 4 to 6 weeks is the subsequent step.
This duration constitutes an adequate trial to observe the full therapeutic benefits of the medication.
4
Decide on the appropriate management strategy for a failed initial treatment trial.
Augmenting or switching the antidepressant is the final step in this clinical sequence.
Treatment escalation is indicated only after an adequate initial trial fails to produce remission.

Key Concept

The foundational stepped-care management of Major Depressive Disorder requires ruling out bipolar disorder prior to initiating a first-line antidepressant, followed by an adequate trial period of 4 to 6 weeks before considering augmentation or switching strategies.
Estimated Time:1m 0s
Question 3Question →

A 61-year-old retired engineer is brought to the physician by his daughter for a psychiatric evaluation. Over the past five weeks, he has become increasingly withdrawn, spending most of the day in bed. He reports waking up at 3:00 AM daily and being unable to return to sleep. His daughter notes he has lost approximately 5.5 kg (12 lb) during this period and no longer shows interest in his usual hobbies, such as gardening. Two weeks ago, the patient's primary care provider diagnosed him with a major depressive episode and prescribed fluoxetine. The patient states he feels no better and wants to discontinue the medication. Upon further questioning, the daughter recalls that when her father was in his late thirties, he was briefly given a different antidepressant for sadness. Within days of starting that medication, he became excessively talkative, slept only two hours a night for a week, and impulsively bought three luxury vehicles, leading to a brief psychiatric hospitalization. Medical history is otherwise unremarkable, and he takes no other medications. Vital signs are within normal limits. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Discontinue fluoxetine and initiate quetiapine

Answer

Discontinue fluoxetine and initiate quetiapine
This patient is currently experiencing a severe depressive episode, characterized by melancholic features such as terminal insomnia (waking at 3:00 AM), anhedonia, and weight loss. Crucially, his history reveals an episode of severely elevated mood, decreased need for sleep, impulsivity, and hospitalization that occurred after antidepressant exposure. This presentation meets the criteria for a manic episode (antidepressant-induced mania is considered indicative of underlying Bipolar I disorder if the manic symptoms persist beyond the physiological effect of the drug, or in classical definitions, dictates a bipolar spectrum approach). For patients with bipolar depression, standard antidepressant monotherapy (like fluoxetine) is contraindicated as it carries a high risk of inducing a manic switch or rapid cycling. The appropriate next step is to immediately discontinue the fluoxetine and initiate a medication approved for bipolar depression, such as quetiapine, lurasidone, or lithium.

Step-by-Step Solution

1
Analyze the current clinical presentation.
The patient exhibits a major depressive episode with melancholic features (terminal insomnia, significant weight loss, profound anhedonia).
Establishing the current affective state is required for guiding immediate pharmacotherapy.
2
Evaluate the patient's psychiatric history.
The patient had a previous episode of decreased need for sleep, hyper-verbal speech, and impulsivity requiring hospitalization shortly after starting an antidepressant.
A history of mania or hypomania fundamentally changes the diagnosis from Major Depressive Disorder (unipolar) to Bipolar Disorder.
3
Determine the appropriate pharmacologic management based on the revised diagnosis.
The diagnosis is Bipolar I disorder, currently in a depressive episode. The current treatment (fluoxetine monotherapy) is contraindicated.
Antidepressant monotherapy can trigger manic episodes in bipolar patients. The SSRI must be stopped, and a medication efficacious for bipolar depression (e.g., quetiapine, lurasidone, or lithium) should be initiated.

Key Concept

Patients presenting with a depressive episode must be rigorously screened for a history of mania or hypomania prior to initiating, or continuing, antidepressant therapy. Antidepressant monotherapy is contraindicated in Bipolar Disorder due to the risk of inducing mania.
Estimated Time:1m 30s
Question 4Question →

Match each patient's clinical presentation with the most appropriate next step in pharmacological or procedural management.

Click a left item, then click its matching right item

Items

A 72-year-old man with a 6-week history of severe depressed mood, a 15-lb (6.8-kg) weight loss, and the steadfast conviction that his intestines are rotting as a punishment for past sins. He is currently refusing all food and fluids.
A 55-year-old man with a 4-month history of pervasive sadness, anhedonia, and poor concentration, accompanied by a 2-year history of bilateral, symmetrical burning pain in his lower extremities due to poorly controlled diabetes mellitus.
A 28-year-old woman presenting with severe depression and psychomotor retardation. Chart review reveals a past emergency department visit three years prior for a two-week period of decreased need for sleep, pressured speech, and reckless spending.
A 45-year-old woman with major depressive disorder who reports a partial (50%) improvement in symptoms after 8 weeks of escitalopram at the maximum tolerated dose. She continues to struggle with residual fatigue but denies suicidal ideation.

Matches

Show answer & explanation

Answer

The 72-year-old man with psychotic depression and food refusal matches with Electroconvulsive therapy. The 55-year-old man with depression and diabetic neuropathy matches with Duloxetine monotherapy. The 28-year-old woman with a history of mania matches with Quetiapine monotherapy. The 45-year-old woman with a partial response to escitalopram matches with Aripiprazole augmentation.
Each patient represents a specific clinical scenario requiring tailored psychiatric management. The elderly patient in a life-threatening state due to psychotic depression requires ECT. The patient with comorbid painful neuropathy benefits from duloxetine's dual SNRI action. The young woman with past mania requires an atypical antipsychotic approved for bipolar depression (quetiapine). The patient with a robust but incomplete response to an SSRI requires augmentation (aripiprazole).

Step-by-Step Solution

1
Analyze the 72-year-old man's presentation.
Identified major depressive disorder with psychotic features (delusions of rotting intestines) and life-threatening oral intake refusal.
This establishes an indication for urgent, definitive treatment rather than waiting weeks for pharmacotherapy to take effect.
2
Analyze the 55-year-old man's presentation.
Identified major depressive disorder with comorbid neuropathic pain (diabetic peripheral neuropathy).
Guides the selection of a dual-action antidepressant (SNRI) that addresses both mood and neuropathic pain pathways.
3
Analyze the 28-year-old woman's presentation.
Identified a current depressive episode in a patient with a clear history of a manic episode (decreased sleep, pressured speech, impulsivity).
Changes the diagnosis from unipolar major depressive disorder to bipolar I disorder, fundamentally altering the pharmacological approach.
4
Analyze the 45-year-old woman's presentation.
Identified treatment-resistant depression defined by a partial response to an adequate 8-week trial of an SSRI at maximum dose.
Determines that augmenting the current regimen to capitalize on the partial response is superior to cross-titrating to a new monotherapy.

Key Concept

Tailoring management of depressive disorders based on clinical specifiers (e.g., psychotic features), comorbidities, treatment history, and bipolar risk.
Question 5Question →

Match the following patient clinical profiles with the most appropriate next step in management.

Click a left item, then click its matching right item

Items

70-year-old man, 3 weeks post-myocardial infarction, meeting criteria for major depressive disorder.
28-year-old woman in her first trimester of pregnancy with psychotic depression and refusal of oral intake.
40-year-old man with major depressive disorder, experiencing persistent sexual dysfunction and fatigue on an SSRI.
25-year-old woman with major depressive disorder characterized by prominent insomnia and significant weight loss.
22-year-old man with severe depression and a history of a 7-day period of euphoric mood, grandiosity, and decreased need for sleep.

Matches

Show answer & explanation

Answer

The most appropriate management strategies are matched as follows: the post-myocardial infarction patient with sertraline, the pregnant patient with psychotic depression with urgent electroconvulsive therapy, the patient with SSRI-induced sexual dysfunction with bupropion augmentation, the patient with insomnia and weight loss with mirtazapine, and the patient with a history of mania with quetiapine.
The correct matches align specific interventions with the unique clinical presentations of each patient, ensuring efficacy while minimizing risks and addressing prominent side effects or symptoms.

Step-by-Step Solution

1
Assess the cardiovascular risk profile of the 70-year-old man.
Identify that a post-myocardial infarction status requires a medication with high cardiac safety.
Tricyclic antidepressants and some SSRIs can cause arrhythmias or interact with cardiac medications; sertraline is proven safe.
2
Evaluate the acuity of the 28-year-old pregnant woman.
Determine that psychosis and food refusal necessitate a rapid, life-saving intervention.
Electroconvulsive therapy is highly effective and safe for both the mother and fetus in psychiatric emergencies.
3
Analyze the side effect burden of the 40-year-old man.
Recognize that SSRI-induced sexual dysfunction and residual fatigue require a mechanism change.
Adding an NDRI like bupropion targets these specific residual symptoms without compounding sexual dysfunction.
4
Identify the prominent neurovegetative symptoms in the 25-year-old woman.
Select an agent that promotes sleep and appetite.
Mirtazapine's antagonism of H1 receptors directly treats her insomnia and weight loss.
5
Recognize the past manic episode in the 22-year-old man's history.
Diagnose bipolar I depression and select an appropriate mood-stabilizing agent.
Quetiapine treats bipolar depression while avoiding the risk of a manic switch associated with SSRI monotherapy.

Key Concept

Tailoring the pharmacological and procedural management of depressive disorders requires careful consideration of medical comorbidities, prominent symptom profiles, clinical acuity, and past psychiatric history.
Estimated Time:1m 30s
Question 6Question →

Evaluate the clinical scenarios below and match each patient to the most appropriate next step in psychiatric management.

Click a left item, then click its matching right item

Items

A 31-year-old primigravida at 14 weeks gestation is brought for urgent psychiatric evaluation. She exhibits profound psychomotor retardation and a steadfast, delusional belief that her internal organs are decomposing. She has refused all food and fluids for five days and appears severely dehydrated.
An otherwise healthy 24-year-old woman seeks help for a two-month history of sleeping 14 hours a day, hyperphagia, and severe depressed mood. Her medical history reveals a hospitalization three years ago following a two-week period of sleeplessness, pressured speech, and grandiose delusions. She currently takes no medications.
Three weeks following an anterior ST-elevation myocardial infarction complicated by heart failure, a 58-year-old man develops pervasive sadness, feelings of worthlessness, and passive suicidal ideation that severely impacts his cardiac rehabilitation.
A 52-year-old man with chronic, severe depression presents for consultation. He continues to experience debilitating anhedonia despite documented, adequate therapeutic trials of escitalopram, duloxetine, and venlafaxine augmented with aripiprazole. He adamantly refuses electroconvulsive therapy due to fears of memory impairment.

Matches

Show answer & explanation

Answer

The pregnant patient with inanition requires inpatient admission and ECT. The 24-year-old woman with a history of mania requires quetiapine monotherapy. The post-MI patient should be started on sertraline. The patient with treatment-resistant depression refusing ECT should receive intranasal esketamine.
Each correct pairing matches a nuanced psychiatric presentation with its safest and most evidence-based management strategy. ECT provides the rapid response required for inanition in pregnancy. Quetiapine treats bipolar depression without risking manic switch. Sertraline provides cardiac safety post-MI. Esketamine bypasses treatment resistance when ECT is refused.

Step-by-Step Solution

1
Analyze the pregnant patient's presentation (Left 1).
Identified psychotic depression with life-threatening inanition and fluid refusal.
Determines the need for rapid, safe intervention (ECT) over slower-acting pharmacotherapy, prioritizing fetal and maternal survival.
2
Evaluate the 24-year-old woman's history (Left 2).
Recognized a current depressive episode in the context of a past hospitalized manic episode (Bipolar I disorder).
Avoids the critical error of prescribing antidepressant monotherapy, guiding the choice toward bipolar-specific treatments like quetiapine.
3
Assess the 58-year-old man's medical comorbidities (Left 3).
Identified major depressive disorder occurring post-myocardial infarction.
Dictates the selection of a cardiac-safe antidepressant with low potential for CYP450 interactions, making sertraline the optimal choice.
4
Review the 52-year-old man's treatment history (Left 4).
Confirmed treatment-resistant depression (failed >2 classes) with a specific refusal of electroconvulsive therapy.
Guides the selection of advanced TRD therapies, specifically intranasal esketamine, which is evidence-based for this exact presentation.

Key Concept

Management of depressive disorders requires tailoring interventions to specific subtypes (e.g., psychotic features), identifying bipolar vs. unipolar disease to avoid manic switch, ensuring cardiovascular safety in comorbid patients, and escalating to interventional therapies for treatment resistance.
Question 7Question →

A 3131-year-old man presents via telehealth for an initial psychiatric evaluation. He reports a 77-week history of persistent low mood, extreme lethargy, and a 66-kg (1313-lb) weight gain. He sleeps up to 1515 hours a day and describes his limbs as feeling 'unnaturally heavy.' For the past 22 weeks, he has also been hearing a distinct, critical voice telling him he is 'toxic and contagious' whenever he is alone in his room. Upon detailed psychiatric history taking, he reveals that 33 years ago, he was hospitalized for a 1010-day period during which he believed he was a divine messenger, slept only 11 hour per night, and paced the streets preaching. He was stabilized and discharged but stopped his prescribed medications shortly afterward. He recently began taking a high-dose over-the-counter St. John's wort supplement to improve his mood, but it has provided no relief. A recent primary care blood panel shows a thyroid-stimulating hormone (TSH) level of 2.12.1 mU/L (normal: 0.50.5-5.05.0) and a free thyroxine (T4) level of 1.11.1 ng/dL (normal: 0.80.8-1.81.8). Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue St. John's wort and initiate quetiapine

Answer

The most appropriate next step is to discontinue St. John's wort and initiate quetiapine.
The patient is presenting with a major depressive episode characterized by atypical features (hypersomnia, hyperphagia, leaden paralysis) and psychotic features (auditory hallucinations). Crucially, his history of a 1010-day hospitalization for grandiosity and decreased sleep confirms a diagnosis of Bipolar I Disorder. The most appropriate treatment for acute bipolar depression with psychotic features is an atypical antipsychotic that has demonstrated efficacy in bipolar depression, such as quetiapine or lurasidone. Quetiapine provides both mood-stabilizing effects for the bipolar depression and dopamine antagonism to treat the active psychosis. Additionally, the patient's over-the-counter St. John's wort should be discontinued due to lack of efficacy and a high risk of dangerous pharmacokinetic interactions (it is a potent CYP3A4 inducer and serotonergic agent).

Step-by-Step Solution

1
Analyze the current clinical presentation.
The patient presents with an acute major depressive episode characterized by atypical features (hypersomnia, weight gain, leaden paralysis) and mood-congruent psychotic features (auditory hallucinations for 22 weeks).
Identifying the current symptom cluster dictates the immediate therapeutic targets.
2
Evaluate the past psychiatric and medical history.
A previous hospitalization for a 1010-day episode of severe grandiosity, lack of sleep, and impaired functioning defines a prior manic episode. The thyroid panel is normal.
A history of mania changes the diagnosis from Major Depressive Disorder to Bipolar I Disorder, fundamentally altering the pharmacologic algorithm and ruling out unipolar depression and organic causes.
3
Determine the optimal pharmacotherapy while avoiding drug interactions.
St. John's wort must be discontinued due to inefficacy and interaction risks. Quetiapine is selected as it is approved for bipolar depression and provides D2 blockade for his psychotic features.
Monotherapy with traditional antidepressants must be avoided in bipolar depression. An atypical antipsychotic covers both the mood and psychotic symptoms safely.

Key Concept

Bipolar I Disorder, Current Episode Depressed with Psychotic and Atypical Features
Estimated Time:1m 30s
Question 8Question →

A 37-year-old man comes to the psychiatrist complaining of feeling "completely empty" for the past 2 months. He reports that he has lost interest in his architectural work, which he usually loves, and struggles to get out of bed before noon. His appetite has decreased, leading to an 8-lb (3.6-kg) weight loss. He expresses intense guilt over a minor calculation mistake he made on a project a year ago. A review of his past medical records reveals an emergency department visit 3 years ago for acute agitation. During that visit, he was speaking so quickly he was difficult to understand, claimed he had discovered the secret to limitless energy, and had not slept in 5 days. He was stabilized on a medication that he subsequently stopped taking because he felt it blunted his creativity. His vital signs and physical examination today are unremarkable. Which of the following is the most appropriate next step in the pharmacologic management of this patient's current symptoms?

Show answer & explanation

Answer: Lurasidone therapy

Answer

Lurasidone therapy
The correct answer is lurasidone therapy. This patient is currently experiencing a major depressive episode, but his history of a distinct period of severe agitation, pressured speech, grandiosity, and decreased need for sleep lasting 5 days (which required emergency stabilization) meets the criteria for a past manic episode. Therefore, his correct diagnosis is bipolar I disorder, currently in a depressed phase (bipolar depression). The first-line pharmacological treatments for bipolar depression include lurasidone, quetiapine, and the olanzapine-fluoxetine combination. Lurasidone is a second-generation (atypical) antipsychotic that effectively treats bipolar depression without the risk of inducing a manic switch.

Step-by-Step Solution

1
Analyze the current clinical presentation.
The patient has a 2-month history of depressed mood, anhedonia, neurovegetative symptoms (weight loss, hypersomnia), and excessive guilt, indicating a major depressive episode.
Identifying the current affective state is the first step in establishing the phase of illness.
2
Evaluate the past psychiatric history.
The history of a distinct period of rapid speech, grandiosity, and decreased need for sleep lasting 5 days (requiring emergency intervention) indicates a past manic episode.
A history of mania changes the primary diagnosis from major depressive disorder (unipolar) to bipolar I disorder.
3
Determine the most appropriate treatment for bipolar depression.
Lurasidone is selected as it is an FDA-approved, first-line atypical antipsychotic for acute bipolar depression.
Antidepressant monotherapy must be avoided in bipolar I disorder due to the severe risk of precipitating a manic switch.

Key Concept

Management of Bipolar Depression
Question 9Question →

Select the most appropriate initial pharmacological or procedural intervention for each of the following patients presenting with distinct clinical features of major depressive disorder.

Click a left item, then click its matching right item

Items

A 72-year-old man with a 4-week history of profound psychomotor retardation, somatic delusions that his internal organs are rotting, and complete refusal to consume any food or fluids.
A 55-year-old man presenting with a 3-month history of significant unintentional weight loss (9 kg), poor appetite, and severe initial and middle insomnia, leading to severe daytime fatigue.
A 48-year-old woman with a newly diagnosed major depressive episode who is also experiencing chronic, bilateral, burning stocking-glove paresthesias secondary to poorly controlled diabetes mellitus.
A 29-year-old woman with a 6-week history of major depressive disorder characterized by prominent lethargy and hypersomnia. She strongly emphasizes her desire to avoid any medication that may cause weight gain or sexual dysfunction.

Matches

Show answer & explanation

Answer

The clinical profiles map to interventions based on side effect profiles and comorbidities: the psychotic/refusing food patient matches with Electroconvulsive therapy; the insomniac/anorexic patient matches with Mirtazapine; the diabetic neuropathy patient matches with Duloxetine; and the lethargic patient avoiding sexual side effects matches with Bupropion.
Each patient's clinical vignette highlights specific indications for a particular therapy. The elderly man with psychotic depression and food refusal requires the rapid, life-saving response of electroconvulsive therapy. The man with severe insomnia and weight loss benefits from the sedating and appetite-stimulating effects of mirtazapine. The woman with diabetic neuropathy is best treated with duloxetine, an SNRI indicated for both conditions. The young woman with hypersomnia who wishes to avoid sexual dysfunction and weight gain is an ideal candidate for the activating NDRI bupropion.

Step-by-Step Solution

1
Analyze the 72-year-old man's presentation.
He has major depressive disorder with psychotic features (somatic delusions) and active food/fluid refusal.
Identifying life-threatening psychiatric emergencies is necessary to select rapid, definitive treatment over delayed pharmacological options.
2
Evaluate the 55-year-old man's vegetative symptoms.
He suffers primarily from weight loss and severe insomnia.
Antidepressants with sedating and appetite-stimulating side effects can simultaneously treat the depression and these specific target symptoms.
3
Identify the 48-year-old woman's comorbid medical condition.
She has painful diabetic neuropathy.
Using an agent that treats both depression and neuropathic pain reduces polypharmacy.
4
Consider the 29-year-old woman's specific aversions.
She is lethargic and wishes to avoid weight gain and sexual dysfunction.
Patient adherence is heavily influenced by side effects, so choosing an activating medication devoid of sexual/weight side effects is optimal.

Key Concept

Tailoring depression treatment based on patient-specific symptom clusters, comorbidities, and medication side-effect profiles.
Question 10Question →

A 28-year-old woman presents to the clinic complaining of feeling "down" and "exhausted" for the past month. She reports struggling to get out of bed, losing interest in her hobbies, and experiencing a 3-kg (6.6-lb) weight gain. She has difficulty concentrating at work. Four years ago, she had a period lasting about a week where she felt "on top of the world," required only 3 hours of sleep a night, and started a business that quickly failed, accumulating significant debt. She is currently not taking any medications. Her vital signs are temperature 37.0°C (98.6°F), blood pressure 110/70 mm Hg, pulse 72/min, and respirations 14/min. Physical examination shows no abnormalities. Laboratory studies show a thyroid-stimulating hormone (TSH) level of 2.1 mU/L2.1 \text{ mU/L} and a free thyroxine (T4) level of 1.2 ng/dL1.2 \text{ ng/dL}. Which of the following is the most appropriate initial pharmacotherapy for this patient?

Show answer & explanation

Answer: Quetiapine

Answer

Quetiapine
The correct answer is quetiapine. This patient presents with a major depressive episode, but her history of a distinct period of abnormally elevated mood, decreased need for sleep, and risky financial behavior lasting a week meets the criteria for a manic episode. Therefore, her diagnosis is bipolar I disorder, currently in a depressed episode. The first-line treatment for bipolar depression includes certain second-generation antipsychotics (e.g., quetiapine, lurasidone) or mood stabilizers (e.g., lithium, lamotrigine). Quetiapine effectively treats the depressive symptoms without significantly increasing the risk of a manic switch.

Step-by-Step Solution

1
Analyze the patient's current symptoms.
The patient has a 1-month history of depressed mood, fatigue, anhedonia, weight gain, and poor concentration, which are indicative of a major depressive episode.
To establish the current clinical state.
2
Review the patient's psychiatric history.
The patient had a 1-week episode of elevated mood, decreased need for sleep, and risky behavior 4 years ago.
To determine if the patient has a history of mania or hypomania, which fundamentally alters the diagnosis and management.
3
Synthesize the findings to formulate a diagnosis.
A history of a manic episode combined with a current major depressive episode is diagnostic of Bipolar I disorder, currently in a depressed episode.
To guide the selection of appropriate pharmacotherapy.
4
Select the appropriate treatment for bipolar depression.
Quetiapine is selected as it is approved for the treatment of bipolar depression and does not carry a high risk of inducing a manic switch.
Antidepressant monotherapy must be avoided in bipolar disorder due to the significant risk of precipitating mania.

Key Concept

Patients presenting with a major depressive episode must be carefully screened for a history of mania or hypomania to rule out bipolar disorder before initiating therapy, as antidepressant monotherapy can precipitate a manic switch.
Question 11Question →

A 42-year-old woman is evaluated in the psychiatric clinic and diagnosed with a moderate major depressive episode without psychotic features. Over the next 18 months, she requires multiple adjustments to her treatment plan due to inadequate symptom relief. Ultimately, her condition deteriorates, and she develops severe psychotic depression with delusions of guilt and total refusal to consume food or fluids. According to standard clinical guidelines for the stepped-care management of major depressive disorder, arrange the following therapeutic interventions in the most appropriate chronological sequence of escalation.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of treatment escalation begins with initiating SSRI monotherapy, followed by switching to an SNRI after an initial non-response, then augmenting with an atypical antipsychotic for partial response, and finally utilizing electroconvulsive therapy (ECT) when the patient develops life-threatening psychotic features and food refusal.
The management of major depressive disorder (MDD) follows a sequential, stepped-care model based on treatment response and symptom severity. For a newly diagnosed, uncomplicated episode, first-line treatment is SSRI monotherapy. If an adequate trial (typically 4-8 weeks at a therapeutic dose) yields no significant improvement, standard guidelines recommend switching to another first-line antidepressant, such as an SNRI or a different SSRI. If a subsequent trial yields a partial response, the addition of an augmenting agent (e.g., an atypical antipsychotic, lithium, or triiodothyronine) is indicated to boost efficacy. Finally, if the patient's condition continues to worsen and they develop life-threatening symptoms—such as psychotic features (delusions/hallucinations), severe suicidality, or refusal to eat and drink—electroconvulsive therapy (ECT) becomes the most urgent and effective treatment of choice.

Step-by-Step Solution

1
Determine the first-line pharmacotherapy for an initial diagnosis of unipolar major depressive disorder.
Initiation of SSRI monotherapy.
SSRIs have a favorable side-effect profile and are the gold standard for initiating MDD treatment.
2
Identify the standard clinical step when a patient exhibits minimal to no response after an adequate SSRI trial (4-8 weeks).
Switching to a different antidepressant (e.g., an SNRI).
Switching monotherapy is preferred over early polypharmacy when the initial agent provides virtually no benefit.
3
Determine the appropriate intervention when a patient achieves only a partial response to a subsequent antidepressant trial.
Augmentation of the current regimen with an evidence-based adjunct (e.g., an atypical antipsychotic).
Augmentation maximizes the partial benefit already achieved by the current antidepressant while minimizing the risk of losing that progress by switching again.
4
Identify the primary indication for electroconvulsive therapy (ECT) in the context of progressive clinical deterioration.
Admission and administration of ECT.
The development of psychotic features and refusal to eat or drink constitutes a psychiatric emergency requiring the rapid, definitive efficacy provided by ECT.

Key Concept

Stepped-care pharmacological escalation and indications for electroconvulsive therapy in major depressive disorder
Question 12Question →

A 22-year-old college student presents to the university outpatient clinic reporting a 5-week history of feeling profoundly sad, crying frequently, and lacking the motivation to attend her classes. She reports sleeping up to 12 hours a day and eating significantly more than usual, resulting in a 4 kg (8.8 lb) weight gain. She has no significant past medical history, and her vital signs are within normal limits. Laboratory tests, including a complete blood count and thyroid-stimulating hormone (TSH) level, are normal. She currently takes no medications or illicit substances. The physician suspects a major depressive episode and plans to prescribe fluoxetine. Which of the following is the most appropriate next step in the clinical evaluation and management of this patient?

Show answer & explanation

Answer: Inquire about any past periods of persistently elevated mood, grandiosity, and decreased need for sleep

Answer

Inquire about any past periods of persistently elevated mood, grandiosity, and decreased need for sleep
The correct next step is to screen for a history of manic or hypomanic episodes. This patient presents with a major depressive episode characterized by atypical features (hypersomnia, weight gain). Before initiating antidepressant monotherapy (e.g., fluoxetine), it is absolutely critical to rule out a history of bipolar disorder. Prescribing an antidepressant to a patient with unrecognized bipolar disorder can precipitate a manic or hypomanic episode (manic switch). Therefore, specifically asking about periods of persistently elevated mood, impulsivity, and decreased need for sleep is mandatory.

Step-by-Step Solution

1
Identify the patient's primary syndrome
The patient meets criteria for a major depressive episode with atypical features (hypersomnia, hyperphagia, leaden paralysis or weight gain).
Establishing the current episode is necessary before determining the treatment plan.
2
Evaluate the planned pharmacological intervention
The physician plans to prescribe an SSRI (fluoxetine).
Antidepressant monotherapy is the standard treatment for unipolar major depressive disorder.
3
Determine the critical prerequisite before initiating an antidepressant
A lifetime history of mania or hypomania must be ruled out.
If the patient has an undiagnosed history of mania or hypomania (Bipolar I or II disorder), SSRI monotherapy can precipitate a manic switch or rapid cycling. Therefore, screening for these symptoms is the most appropriate next step.

Key Concept

All patients presenting with a major depressive episode must be screened for a history of manic or hypomanic episodes before initiating antidepressant monotherapy to avoid precipitating a manic switch.
Question 13Question →

A 26-year-old woman is brought to the clinic by her sister due to a 5-week history of severe depression. The patient describes her mood as "bottomless" and complains that her arms and legs constantly feel "heavy as lead." She reports sleeping 14 to 16 hours daily and has gained 6 kg (13.2 lb) over the past month, which she attributes to intense carbohydrate cravings. Despite her profound sadness, the sister notes that the patient's mood brightened considerably yesterday when she was presented with a surprise gift, though she relapsed into despondency hours later. The patient has experienced two similar depressive episodes in the past. The sister confidentially shares that during the patient's sophomore year of college, there was a distinct 10-day period where she seemed "like a completely different person." During that time, she slept only 3 hours a night without feeling fatigued, rapidly repainted her entire apartment, and abruptly spent her tuition money on a business venture that never materialized. She has no significant past medical history. Physical examination is unremarkable. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

Show answer & explanation

Answer: Initiate quetiapine

Answer

Initiate quetiapine
The correct answer is to initiate quetiapine. This patient is currently experiencing a major depressive episode characterized by atypical features, which include mood reactivity (brightening in response to positive events), hypersomnia, weight gain/hyperphagia, and leaden paralysis (heavy feeling in limbs). Crucially, her history reveals a distinct 10-day period of decreased need for sleep, increased goal-directed activity, and impulsivity. Because this elevated state lasted longer than 4 days and did not result in severe functional impairment or require hospitalization, it meets the criteria for a hypomanic episode. A history of at least one major depressive episode and at least one hypomanic episode establishes the diagnosis of Bipolar II disorder. For the acute treatment of bipolar depression, first-line pharmacotherapy includes specific atypical antipsychotics such as quetiapine, lurasidone, or cariprazine.

Step-by-Step Solution

1
Identify the features of the current depressive episode.
The patient has leaden paralysis, hypersomnia, weight gain, and mood reactivity.
These specifically meet the DSM-5 criteria for a major depressive episode with atypical features.
2
Evaluate the patient's psychiatric history for periods of elevated mood.
The history reveals a 10-day period of decreased need for sleep, increased goal-directed activity, and impulsivity without severe impairment requiring hospitalization.
This establishes a history of a past hypomanic episode, which changes the primary diagnosis from Major Depressive Disorder to Bipolar II disorder.
3
Determine the appropriate pharmacotherapy for acute Bipolar II depression.
First-line agents include quetiapine, lurasidone, or cariprazine. Antidepressant monotherapy must be avoided.
Antidepressants can precipitate a manic or hypomanic switch in patients with bipolar disorder.

Key Concept

Bipolar II Disorder presenting as acute depression with atypical features
Question 14Question →

A 29-year-old woman presents to the clinic 4 weeks postpartum for a follow-up evaluation. She reports feeling profoundly sad, tearful, and unable to enjoy time with her newborn. She states, "I feel completely overwhelmed and guilty for being a terrible mother." She wakes up at 3:00 AM every day and is unable to fall back asleep, despite her husband handling the nighttime feedings. She has a poor appetite and has lost 4.5 kg (10 lb) since her delivery. She denies any thoughts of harming herself or her infant. She had an uncomplicated vaginal delivery but required a second-degree perineal laceration repair; she takes tramadol occasionally for residual pain. When reviewing her psychiatric history, she mentions that during her sophomore year of college, she experienced a distinct 5-day period where she felt "invincible," required only 2 hours of sleep per night, and started three different student organizations while speaking so rapidly her friends could hardly understand her. This college episode resolved spontaneously without hospitalization. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate quetiapine

Answer

Initiate quetiapine
This patient is experiencing a major depressive episode (depressed mood, anhedonia, sleep disturbance, weight loss, severe guilt) with peripartum onset. Crucially, her history of a 5-day period of elevated mood, decreased need for sleep, pressured speech, and increased goal-directed activity without hospitalization meets the criteria for a hypomanic episode. Therefore, her correct diagnosis is Bipolar II disorder. In patients with bipolar depression, monotherapy with standard antidepressants (such as SSRIs) is contraindicated because it can precipitate a hypomanic or manic switch. First-line evidence-based treatments for bipolar depression include certain atypical antipsychotics (e.g., quetiapine, lurasidone, cariprazine) or mood stabilizers. Quetiapine is an excellent choice for this patient, as it treats bipolar depression effectively and is frequently used during the postpartum period due to its well-established safety profile.

Step-by-Step Solution

1
Evaluate the current mood episode based on the patient's presenting symptoms.
The patient presents with severe sadness, anhedonia, early morning awakening, weight loss, and guilt lasting 4 weeks postpartum, which meets the criteria for a major depressive episode with peripartum onset.
To establish the current clinical problem requiring intervention.
2
Analyze the patient's psychiatric history for prior mood episodes.
The patient describes a past 5-day episode of elevated mood, decreased need for sleep, increased goal-directed activity, and pressured speech that resolved without hospitalization, which meets the criteria for a hypomanic episode.
To differentiate between unipolar depression and bipolar depression, which fundamentally alters the treatment approach.
3
Synthesize the current and past history to determine the correct diagnosis.
A history of at least one hypomanic episode and at least one major depressive episode indicates a diagnosis of Bipolar II disorder.
To guide the selection of appropriate pharmacotherapy and avoid contraindicated agents.
4
Select the most appropriate pharmacotherapy for the patient's diagnosis.
First-line treatment for bipolar depression includes atypical antipsychotics such as quetiapine or lurasidone, which treat depression without the risk of inducing a manic switch.
To provide safe and effective management while avoiding contraindicated medications like antidepressant monotherapy.

Key Concept

Patients presenting with a major depressive episode must be carefully screened for a history of mania or hypomania. If a history is present (indicating bipolar disorder), antidepressant monotherapy is contraindicated due to the risk of mood switch, and treatments like quetiapine or lurasidone are preferred.
Estimated Time:1m 30s
Question 15Question →

A 47-year-old male executive seeks psychiatric evaluation for profound sadness, early morning awakening, and severe anhedonia that have progressively worsened over the past four months. His past medical history is unremarkable, and he is currently taking no medications. Arrange the following therapeutic steps in the exact sequence recommended by standard clinical guidelines for the progressive pharmacological and procedural management of major depressive disorder. Assume that each step is implemented sequentially only after the preceding intervention has yielded an inadequate clinical response (either non-response or insufficient partial response) despite optimal dosing and duration.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: initiate an SSRI, switch to an SNRI upon non-response, augment with an atypical antipsychotic or lithium upon partial response, and finally utilize ECT for established treatment-resistant depression.
The established clinical algorithm for the progressive management of major depressive disorder prioritizes sequential, stepped interventions to balance efficacy and tolerability. The foundation of treatment begins with an initial monotherapy trial of a first-line agent, most commonly an SSRI. If the patient exhibits non-response after an adequate duration (typically 4-8 weeks at a therapeutic dose), the standard next step is to switch to a different monotherapy, often of another class such as an SNRI or an NDRI (like bupropion). Should this second trial yield only a partial response, the addition of an augmentation agent—such as a second-generation antipsychotic (e.g., aripiprazole, quetiapine), lithium, or triiodothyronine (T3)—is recommended to optimize the existing response. Finally, if the patient continues to experience severe, treatment-resistant depression after multiple failed trials of different pharmacologic classes and augmentation strategies, non-pharmacologic neuromodulation, specifically electroconvulsive therapy (ECT), is indicated as the definitive next step.

Step-by-Step Solution

1
Determine the optimal initial treatment for the patient.
Select SSRI monotherapy.
The patient has a new, severe major depressive episode without prior treatment, making an SSRI the first-line standard of care.
2
Determine the next step following the failure of the initial monotherapy.
Switch to an alternative agent of a different class, such as an SNRI.
When a patient shows non-response to an adequate initial SSRI trial, clinical guidelines strongly recommend switching to another first-line agent, often from a different class.
3
Determine the management approach for an inadequate response to the second trial.
Augment the current therapy with an adjunctive agent like an atypical antipsychotic or lithium.
If the patient achieves only a partial response to the second antidepressant trial, augmentation is employed to boost efficacy rather than entirely abandoning the trial.
4
Identify the definitive approach for profound treatment resistance.
Refer for electroconvulsive therapy (ECT).
After the failure of multiple distinct medication trials involving different classes and augmentation, the patient meets criteria for treatment-resistant depression, making ECT highly appropriate and effective.

Key Concept

The stepped-care approach to treatment-resistant major depressive disorder requires a progressive escalation from SSRI monotherapy to switching medication classes, followed by augmentation strategies, and ultimately procedural interventions such as ECT.
Question 16Question →

A 29-year-old man presents to the outpatient clinic reporting a 6-week history of feeling "down and hopeless." He states that he has lost interest in his usual hobbies, has very low energy, and is sleeping up to 12 hours a day. His appetite has increased, leading to a 4-kg (8.8-lb) weight gain. He was recently reprimanded at work for excessive absences because he could not find the motivation to get out of bed. He has no significant past medical history and takes no medications. He does not use tobacco, alcohol, or illicit substances. He mentions that occasionally, just as he is falling asleep, he hears a voice calling his name. Physical examination reveals a flat affect and psychomotor retardation, but no other abnormalities. He requests to be started on an antidepressant medication. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Assess for a history of elevated mood and decreased need for sleep

Answer

The most appropriate next step is to assess for a history of elevated mood and decreased need for sleep.
The correct answer is to assess for a history of elevated mood and decreased need for sleep. This patient is presenting with a severe major depressive episode characterized by depressed mood, anhedonia, hypersomnia, weight gain, profound fatigue, and functional impairment lasting >2 weeks. However, a major depressive episode can be the presenting phase of either Major Depressive Disorder (MDD) or Bipolar Disorder. Because the cross-sectional depressive symptoms are identical in both conditions, the standard of care mandates that all patients presenting with depression be explicitly screened for a history of manic or hypomanic episodes (e.g., periods of persistently elevated or irritable mood, decreased need for sleep, impulsivity, grandiosity) before initiating antidepressant medication. Prescribing antidepressant monotherapy to a patient with unrecognized bipolar disorder carries a significant risk of precipitating an acute manic or hypomanic episode (often referred to as a "manic switch"). The patient's auditory hallucination as he is falling asleep is a hypnagogic hallucination, which is a normal variant and does not mandate a primary psychotic disorder workup.

Step-by-Step Solution

1
Identify the patient's primary syndrome based on the clinical presentation.
The patient is experiencing a major depressive episode.
He has >5 symptoms of depression (depressed mood, anhedonia, fatigue, hypersomnia, weight gain) lasting >2 weeks with significant functional impairment.
2
Evaluate the reported auditory phenomenon.
The patient is experiencing hypnagogic hallucinations.
Hearing a voice or name just as one is falling asleep is a normal physiological variant and does not indicate a true psychotic disorder like schizophrenia.
3
Determine the necessary evaluation step prior to initiating pharmacotherapy.
Screen for a history of bipolar disorder (mania or hypomania).
Major depressive episodes can occur in both Major Depressive Disorder and Bipolar Disorder. Unopposed antidepressant monotherapy in a patient with bipolar disorder can precipitate a manic switch. Therefore, all patients must be screened for past manic/hypomanic episodes before antidepressants are prescribed.

Key Concept

Prior to initiating antidepressant monotherapy for a major depressive episode, patients must be explicitly screened for a history of manic or hypomanic episodes to rule out bipolar disorder and prevent antidepressant-induced mania.
Estimated Time:1m 0s
Question 17Question →

A 34-year-old woman presents to the clinic with a 6-week history of profound sadness, anhedonia, and terminal insomnia. She reports significant functional impairment, having recently taken a leave of absence from her job due to a severe inability to concentrate. Review of systems is notable for a 4.5-kg (10-lb) weight loss and mild psychomotor agitation. Thorough psychiatric screening confirms the absence of any past manic or hypomanic episodes, ruling out bipolar disorder. Over the next 14 months, her major depressive disorder exhibits a complex trajectory, requiring a progressive, stepped-care escalation of her management plan according to standard psychiatric guidelines. Arrange the following clinical interventions in the most appropriate chronological sequence, beginning with her initial presentation and escalating to the management of life-threatening psychiatric complications.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence of management is: (1) Initiate a first-line SSRI, (2) Titrate the SSRI to the maximum dose for inadequate response, (3) Switch to a different antidepressant class for complete non-response, (4) Augment with a second-generation antipsychotic for partial response, and (5) Proceed with ECT for life-threatening complications.
The standard stepped-care algorithm for major depressive disorder prioritizes single-agent optimization before increasing complexity. Treatment begins with initiating a first-line agent, such as an SSRI. If the initial dose yields inadequate results after an appropriate timeframe (4-6 weeks), the dose must be optimized to the maximum tolerated level. If there is a complete lack of response to the optimized dose, switching to a different class (e.g., SNRI) is indicated to target different neurotransmitters. If a subsequent trial results in a partial response, augmenting with a second agent (e.g., aripiprazole, lithium) is preferred to build on the existing improvement. Finally, if the depression becomes completely treatment-resistant and progresses to life-threatening symptoms (such as active suicidality or food refusal), electroconvulsive therapy (ECT) becomes the urgent intervention of choice.

Step-by-Step Solution

1
Initiate pharmacotherapy with a first-line SSRI.
Establishes baseline pharmacotherapy for the acute depressive episode.
SSRIs are the first-line standard of care for uncomplicated major depressive disorder after ruling out bipolar disorder.
2
Titrate the initial SSRI to the maximum tolerated dose.
Achieves the maximum potential therapeutic effect of the initial agent.
Premature discontinuation is a common error; a trial must be optimized to maximum tolerated doses for at least 4-6 weeks before being declared a failure.
3
Cross-titrate to an antidepressant with a different mechanism of action (e.g., SNRI).
Switches the neurochemical target to overcome complete non-response.
Switching classes is preferred over augmentation when there is a complete lack of response to an optimized initial monotherapy trial.
4
Augment the second antidepressant with a second-generation antipsychotic.
Builds upon the partial clinical improvement achieved by the second agent.
Augmentation is the preferred evidence-based strategy when the current agent provides partial efficacy, avoiding the loss of partial gains that might occur with another switch.
5
Proceed with electroconvulsive therapy (ECT).
Provides definitive, rapid symptom relief for treatment-resistant depression.
ECT becomes necessary and life-saving when treatment-resistant depression progresses to include emergent complications like food refusal, catatonia, or active suicidality.

Key Concept

Stepped-care treatment escalation for major depressive disorder.
Question 18Question →

A 54-year-old software developer with no prior psychiatric history is evaluated for Major Depressive Disorder (MDD). Arrange the following pharmacological and somatic management steps in the correct chronological sequence according to standard stepped-care escalation protocols, starting from the initial presentation to the eventual management of a severe, life-threatening refractory state.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of treatment escalation for MDD is: 1) Initiate SSRI monotherapy, 2) Switch to an SNRI for non-response, 3) Augment with an atypical antipsychotic for partial response, and 4) Administer ECT for life-threatening treatment-resistant depression.
The correct stepped-care escalation for major depressive disorder begins with SSRI monotherapy. If there is no response, switching to a different antidepressant (like an SNRI) is indicated. If there is a subsequent partial response, augmentation (e.g., with an atypical antipsychotic) is preferred to maximize the partial gains. Finally, if the patient becomes completely treatment-resistant and develops life-threatening complications like food refusal, ECT is the definitive, rapid-acting treatment of choice.

Step-by-Step Solution

1
Identify the appropriate first-line treatment for an initial MDD diagnosis.
Initiation of an SSRI.
SSRIs have a favorable side-effect profile and are the universally recommended starting point for uncomplicated MDD.
2
Determine the best management strategy for a patient who shows absolutely no response to the first-line agent after an adequate trial.
Switch to an alternative monotherapy (e.g., an SNRI).
Switching minimizes polypharmacy and is preferred when the initial drug provides zero benefit.
3
Determine the next step if the second agent provides only partial symptom relief.
Augmentation with an adjunctive agent like an atypical antipsychotic.
Augmentation builds upon the partial response already achieved without having to cross-taper and risk losing those partial gains.
4
Identify the definitive treatment for refractory depression that has become acutely life-threatening.
Electroconvulsive therapy (ECT).
ECT provides rapid, definitive treatment for severe depression complicated by immediate physical risks such as starvation from food refusal.

Key Concept

The stepped-care approach to Major Depressive Disorder involves initiating first-line monotherapy, switching agents for complete non-response, augmenting for partial response, and utilizing somatic therapies like ECT for severe, treatment-resistant, or life-threatening disease.
Question 19Question →

A 31-year-old woman is evaluated in the clinic for severe mood changes. She delivered her first child 5 months ago without complications. Over the past 8 weeks, she has experienced profound sadness, anhedonia, and a 5-kg (11-lb) weight loss. She awakens at 3:00 AM daily and cannot return to sleep. She notes her depressed mood is worst in the mornings and is completely unreactive to positive events, including playing with her infant. Two weeks ago, her primary care physician prescribed escitalopram; however, she discontinued it 4 days ago, stating it was ineffective. Her husband reports that five years ago, she had a 7-day episode where she slept only 2 hours per night, spoke incessantly, and compulsively purchased thousands of dollars of baby clothes despite not being pregnant. She has no other medical conditions and does not use illicit substances. Vital signs and physical examination are unremarkable. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Begin treatment with quetiapine

Answer

Begin treatment with quetiapine
The correct action is to begin treatment with quetiapine. This patient presents with a major depressive episode featuring melancholic characteristics. However, her history of a 7-day period of decreased sleep, pressured speech, and severe impulsivity establishes a diagnosis of Bipolar I disorder. The standard of care for bipolar depression includes atypical antipsychotics such as quetiapine or lurasidone, or mood stabilizers like lithium, to treat the depression without risking a manic switch.

Step-by-Step Solution

1
Identify the current clinical syndrome from the patient's presentation.
The patient is currently experiencing a major depressive episode with melancholic features, characterized by anhedonia, early morning awakenings, unreactive mood, and significant weight loss occurring in the postpartum period.
Establishing the current episode dictates the immediate need for psychiatric intervention.
2
Evaluate the patient's psychiatric history for previous mood episodes.
The husband describes a distinct past episode of decreased need for sleep, pressured speech, and severe impulsivity lasting 7 days, which meets the criteria for a manic episode.
A history of mania completely changes the diagnostic framework from unipolar depression to bipolar disorder.
3
Formulate the correct diagnosis and select the appropriate pharmacotherapy.
The diagnosis is Bipolar I disorder, currently in a depressed episode. The most appropriate treatment is an atypical antipsychotic approved for bipolar depression, such as quetiapine or lurasidone.
Antidepressant monotherapy is contraindicated in bipolar disorder due to the high risk of inducing a manic switch.

Key Concept

Patients presenting with a major depressive episode must be screened for a history of mania or hypomania; if present, the diagnosis is bipolar disorder, and treatment requires a mood stabilizer or approved atypical antipsychotic rather than antidepressant monotherapy.
Question 20Question →

A psychiatry resident is evaluating five different patients presenting with depressive symptoms in various clinical settings. Match each patient's clinical vignette with the most appropriate best next step in management or definitive diagnosis.

Click a left item, then click its matching right item

Items

A 68-year-old male, recovering 3 weeks post-myocardial infarction, exhibits a 3-week history of persistently depressed mood, early morning awakenings, and loss of interest in his family.
A 42-year-old female with severe major depressive disorder has refused all food and water for 5 days, expressing steadfast delusions that her internal organs have turned to dust.
A 29-year-old male presents with severe depression and hypersomnia. His medical history includes a distinct 2-week period last year of decreased need for sleep, intense grandiosity, and reckless spending.
A 31-year-old female describes chronic low mood, fatigue, and poor self-esteem persisting for the past 3 years. These symptoms have never abated for more than a month at a time.
A 26-year-old female, 3 weeks postpartum, reports severe depression, crying spells, and intrusive, terrifying thoughts of intentionally drowning her newborn during bath time.

Matches

Show answer & explanation

Answer

Match each vignette to its specific targeted intervention: post-myocardial infarction depression requires sertraline; psychotic depression with starvation requires ECT; bipolar depression requires an atypical antipsychotic like lurasidone; chronic subthreshold depressive symptoms lasting over 2 years indicate persistent depressive disorder; and postpartum depression with infanticidal ideation demands immediate inpatient hospitalization.
Each patient presentation contains specific high-yield clinical clues that dictate a unique management pathway. Post-MI patients need cardiac-safe SSRIs (sertraline). Life-threatening psychotic depression requires rapid intervention (ECT). Bipolar depression must be treated with mood stabilizers or specific atypical antipsychotics (lurasidone) to avoid manic switching. Chronic low-grade depression is classified as persistent depressive disorder. Postpartum depression with infanticidal thoughts is an absolute indication for emergency psychiatric hospitalization.

Step-by-Step Solution

1
Evaluate the 68-year-old male post-MI.
He has major depressive disorder. Sertraline is the safest SSRI for patients with recent cardiac events.
Sertraline avoids QTc prolongation and dangerous drug interactions commonly seen with other agents.
2
Evaluate the 42-year-old female refusing oral intake.
She has psychotic depression with life-threatening starvation. ECT is indicated.
ECT provides the most rapid response for life-threatening psychiatric emergencies when waiting for oral medications is too dangerous.
3
Evaluate the 29-year-old male with prior grandiosity and decreased sleep.
The history of mania indicates bipolar I disorder. Lurasidone is indicated.
Standard antidepressants can trigger manic switching in bipolar disorder and should be avoided as monotherapy.
4
Evaluate the 31-year-old female with 3 years of continuous mild depression.
The timeline and severity point to persistent depressive disorder (dysthymia).
Symptoms have lasted >2 years without a 2-month break and never met full major depressive episode criteria.
5
Evaluate the 26-year-old postpartum female with thoughts of harming her baby.
This is a psychiatric emergency requiring inpatient admission.
Active infanticidal ideation requires immediate action to ensure the infant's safety.

Key Concept

Management of Depressive Disorders across special populations requires tailoring therapy based on medical comorbidities, risk of self-harm or harm to others, and accurate differentiation from bipolar spectrum disorders.
Estimated Time:2m 0s
Page 1 / 6Next
Depressive Disorders Practice Questions — USMLE Step 2 CK | Examkin